These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 16522810)

  • 1. Long-lasting CCR5 internalization by antibodies in a subset of long-term nonprogressors: a possible protective effect against disease progression.
    Pastori C; Weiser B; Barassi C; Uberti-Foppa C; Ghezzi S; Longhi R; Calori G; Burger H; Kemal K; Poli G; Lazzarin A; Lopalco L
    Blood; 2006 Jun; 107(12):4825-33. PubMed ID: 16522810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CCR5-reactive antibodies in seronegative partners of HIV-seropositive individuals down-modulate surface CCR5 in vivo and neutralize the infectivity of R5 strains of HIV-1 In vitro.
    Lopalco L; Barassi C; Pastori C; Longhi R; Burastero SE; Tambussi G; Mazzotta F; Lazzarin A; Clerici M; Siccardi AG
    J Immunol; 2000 Mar; 164(6):3426-33. PubMed ID: 10706739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-CCR5 antibodies in sera of HIV-positive individuals.
    Grene E; Pinto LA; Landay AL; Kessler HA; Anderson SA; Dolan MJ; Shearer GM
    Hum Immunol; 2001 Feb; 62(2):143-5. PubMed ID: 11182224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new prospective against HIV infection: induction of murin CCR5-downregulating antibodies.
    Barassi C; Marenzi C; Pastori C; Longhi R; Lazzarin A; Lopalco L
    New Microbiol; 2004 Apr; 27(2 Suppl 1):85-94. PubMed ID: 15646069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of murine mucosal CCR5-reactive antibodies as an anti-human immunodeficiency virus strategy.
    Barassi C; Soprana E; Pastori C; Longhi R; Buratti E; Lillo F; Marenzi C; Lazzarin A; Siccardi AG; Lopalco L
    J Virol; 2005 Jun; 79(11):6848-58. PubMed ID: 15890924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The number of CCR5 expressing CD4+ T lymphocytes is lower in HIV-infected long-term non-progressors with viral control compared to normal progressors: a cross-sectional study.
    Meijerink H; Indrati AR; van Crevel R; Joosten I; Koenen H; van der Ven AJ
    BMC Infect Dis; 2014 Dec; 14():683. PubMed ID: 25495598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns of in vitro anti-human immunodeficiency virus type 1 antibody production in long-term nonprogressors.
    Rusconi S; Berlusconi A; Papagno L; Colombo MC; De Maddalena C; Riva A; Bagnarelli P; Balotta C; Galli M
    Clin Immunol Immunopathol; 1997 Dec; 85(3):320-3. PubMed ID: 9400632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CCR5 and CXCR4 expression on memory and naive T cells in HIV-1 infection and response to highly active antiretroviral therapy.
    Nicholson JK; Browning SW; Hengel RL; Lew E; Gallagher LE; Rimland D; McDougal JS
    J Acquir Immune Defic Syndr; 2001 Jun; 27(2):105-15. PubMed ID: 11404531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterozygosity for a defective gene for CC chemokine receptor 5 is not the sole determinant for the immunologic and virologic phenotype of HIV-infected long-term nonprogressors.
    Cohen OJ; Vaccarezza M; Lam GK; Baird BF; Wildt K; Murphy PM; Zimmerman PA; Nutman TB; Fox CH; Hoover S; Adelsberger J; Baseler M; Arthos J; Davey RT; Dewar RL; Metcalf J; Schwartzentruber DJ; Orenstein JM; Buchbinder S; Saah AJ; Detels R; Phair J; Rinaldo C; Margolick JB; Pantaleo G; Fauci AS
    J Clin Invest; 1997 Sep; 100(6):1581-9. PubMed ID: 9294127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Constitutive cell surface association between CD4 and CCR5.
    Xiao X; Wu L; Stantchev TS; Feng YR; Ugolini S; Chen H; Shen Z; Riley JL; Broder CC; Sattentau QJ; Dimitrov DS
    Proc Natl Acad Sci U S A; 1999 Jun; 96(13):7496-501. PubMed ID: 10377443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequency of CCR5-Delta32 deletion in human immunodeficiency virus type 1 (HIV-1) in healthy blood donors, HIV-1-exposed seronegative and HIV-1-seropositive individuals of southern Brazilian population.
    Reiche EM; Ehara Watanabe MA; Bonametti AM; Morimoto HK; Akira Morimoto A; Wiechmann SL; Matsuo T; Carvalho De Oliveira J; Vissoci Reiche F
    Int J Mol Med; 2008 Nov; 22(5):669-75. PubMed ID: 18949389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence as a HIV-1 self-defense vaccine of cyclic chimeric dodecapeptide warped from undecapeptidyl arch of extracellular loop 2 in both CCR5 and CXCR4.
    Misumi S; Takamune N; Ido Y; Hayashi S; Endo M; Mukai R; Tachibana K; Umeda M; Shoji S
    Biochem Biophys Res Commun; 2001 Aug; 285(5):1309-16. PubMed ID: 11478800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of highly active antiretroviral treatment on expression of HIV-1 coreceptors and ligand levels in peripheral blood from HIV-1 infected patients in China.
    Fang J; Bai S; Wu L; Zhu X; Yao X; Jin C; Wang C
    J Int Med Res; 2013 Oct; 41(5):1560-9. PubMed ID: 24043708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two amino acid substitutions within the first external loop of CCR5 induce human immunodeficiency virus-blocking antibodies in mice and chickens.
    Pastori C; Clivio A; Diomede L; Consonni R; De Mori GM; Longhi R; Colombo G; Lopalco L
    J Virol; 2008 Apr; 82(8):4125-34. PubMed ID: 18256149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of HIV-blocking anti-CCR5 IgA in Peyers's patches without histopathological alterations.
    Pastori C; Diomede L; Venuti A; Fisher G; Jarvik J; Bomsel M; Sanvito F; Lopalco L
    J Virol; 2014 Apr; 88(7):3623-35. PubMed ID: 24403594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ERK1-Based Pathway as a New Selective Mechanism To Modulate CCR5 with Natural Antibodies.
    Venuti A; Pastori C; Siracusano G; Riva A; Sciortino MT; Lopalco L
    J Immunol; 2015 Oct; 195(7):3045-57. PubMed ID: 26324779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bovine alpha-2-HS-glycoprotein functions as a booster antigen for efficiently stimulating humoral immune responses to CCR5 and SIVmac239 envelope glycoprotein.
    Otsubo Y; Yashiro S; Nozaki K; Matsuura K; Kiyonaga K; Mitsumata R; Takahashi Y; Masuyama M; Muneoka A; Takamune N; Shoji S; Misumi S
    Biochem Biophys Res Commun; 2014 Jan; 443(1):301-7. PubMed ID: 24309114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of Natural Antibodies to CC Chemokine Receptor 5 in HIV Infection.
    Venuti A; Pastori C; Lopalco L
    Front Immunol; 2017; 8():1358. PubMed ID: 29163468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic polymorphism of CCR5 gene and HIV disease: the heterozygous (CCR5/delta ccr5) genotype is neither essential nor sufficient for protection against disease progression. Swiss HIV Cohort.
    Morawetz RA; Rizzardi GP; Glauser D; Rutschmann O; Hirschel B; Perrin L; Opravil M; Flepp M; von Overbeck J; Glauser MP; Ghezzi S; Vicenzi E; Poli G; Lazzarin A; Pantaleo G
    Eur J Immunol; 1997 Dec; 27(12):3223-7. PubMed ID: 9464809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Expression of co-receptor on different T lymphocytes subpopulations after effective HAART].
    Li D; Wu NP; Bader A; Hoxtermann S; Brockmeyer N
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2003 Apr; 32(2):97-100. PubMed ID: 12734930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.